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This study evaluated azacitidine as treatment of minimal
residual disease (MRD) determined by a sensitive donor
chimerism analysis of CD34
þ blood cells to pre-empt relapse
in patients with CD34
þ myelodysplastic syndromes (MDS) or
acute myeloid leukemia (AML) after allogeneic hematopoietic
stem cell transplantation (HSCT). At a median of 169 days after
HSCT, 20/59 prospectively screened patients experienced a
decrease of CD34
þ donor chimerism to o80% and received
four azacitidine cycles (75mg/m
2/day for 7 days) while in
complete hematologic remission. A total of 16 patients (80%)
responded with either increasing CD34
þ donor chimerism to
X80% (n¼10; 50%) or stabilization (n¼6; 30%) in the absence
of relapse. Stabilized patients and those with a later drop of
CD34
þ donor chimerism to o80% after initial response were
eligible for subsequent azacitidine cycles. A total of 11 patients
(55%) received a median of 4 (range, 1–11) additional cycles.
Eventually, hematologic relapse occurred in 13 patients (65%),
but was delayed until a median of 231 days (range, 56–558)
after initial decrease of CD34
þ donor chimerism to o80%. In
conclusion, pre-emptive azacitidine treatment has an accepta-
ble safety proﬁle and can substantially prevent or delay
hematologic relapse in patients with MDS or AML and MRD
after allogeneic HSCT.
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Introduction
Among standard therapeutic strategies in patients with advanced
myelodysplastic syndromes (MDS) or acute myeloid leukemia
(AML), allogeneic hematopoietic stem cell transplantation
(HSCT) remains the only potentially curative treatment
option.
1–3 Nevertheless, in patients eligible to undergo allo-
geneic HSCT, disease relapse still remains a major cause of
treatment failure.
4–6 Treatment algorithms for relapsed disease
are currently limited to conventional salvage chemotherapy,
second allogeneic HSCT, and donor lymphocyte infusion
(DLI).
5,7–9 However, the majority of patients who relapse after
allogeneic HSCT do not achieve long-term survival.
5,8,10
Furthermore, although DLI can induce sustained second
remission in some patients, severe graft-versus-host disease
(GvHD) is a major complication, often resulting in signiﬁcant
morbidity and mortality.
10,11
In recent years, techniques such as ﬂow cytometric assess-
ment of residual disease, donor chimerism and molecular
analyses of leukemia-speciﬁc fusion genes have been used to
facilitate the detection and monitoring of minimal residual
disease (MRD).
12–16 Although determination of MRD by these
methods may precede morphologic disease detection by weeks,
they are often only applicable in a distinct population of MDS or
AML patients with speciﬁc molecular markers.
13–15,17,18 Donor
chimerism analyses of whole blood or bone marrow cells harbor
a low sensitivity.
13–15,17 In contrast, CD34
þ donor chimerism
analyses are useful and very speciﬁc for monitoring MRD in
patients with MDS or AML following prior allogeneic HSCT,
19,20
because CD34
þ blasts at diagnosis are observed in the majority
of these patients.
13,21,22 This makes CD34
þ donor chimerism
analysis an attractive tool in the management of these patients,
irrespective of leukemia-speciﬁc markers. In fact, we have
shown previously that a decrease of CD34
þ donor cells below
80% in the peripheral blood predicts almost unavoidable
relapse in all patients after a median of 61 days.
23 Relapse
occurs in the majority of the patients even in the presence of
interventions such as immediate interruption of immuno-
suppression or administration of DLI.
10,11,23
One major reason for treatment failure in patients with MRD
is the fact that the kinetics of disease recurrence are usually very
rapid,
11,18 which limits the time for graft-versus-leukemia
effects, for example when using DLI. Furthermore, these
interventions often result in clinically signiﬁcant and life-
threatening GvHD.
10,11 Therefore, to prevent subsequent
hematologic relapse with high efﬁcacy, it would be optimal to
integrate novel treatment strategies that are not only effective at
modifying the natural history of disease and thus preventing
relapse, but that are also well tolerated after HSCT. Azacitidine,
a nucleoside analog of cytidine, is the ﬁrst drug therapy to show
a signiﬁcant survival advantage compared with conventional
care regimens in patients with higher-risk MDS and World
Health Organization (WHO)-deﬁned AML with 20–30% bone
marrow blast count.
24,25 Its favorable toxicity proﬁle further
supports its use for pre-emptive treatment in higher-risk MDS or
AML patients with detectable MRD after allogeneic HSCT.
24–26
Recent results of low-dose azacitidine as maintenance
or salvage therapy in higher-risk MDS and AML patients
after allogeneic HSCT pointed to azacitidine being well
tolerated and associated with prolonged progression-free and
overall survival.
27,28
Herein, we report the results of an open-label, single-center
phase II clinical trial evaluating the efﬁcacy of azacitidine in
the setting of MRD-triggered (decrease of CD34
þ donor
chimerism below 80%) pre-emptive therapy to prevent or delay
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Patients and methods
Study design
The RELapse prevention with AZAcitidine (RELAZA) trial was a
prospective, open-label, single-center phase II study performed
at the University Hospital ‘Carl Gustav Carus’, Technical
University of Dresden in Germany. The study was conducted
in accordance with the Declaration of Helsinki and received
Institutional Review Board approval by the Ethical Board of the
University Hospital of Dresden. The trial was sponsored by the
Technical University of Dresden and registered at http://
clinicaltrials.gov (NCT00422890). Written informed consent
was given by all patients. UP, CT, and FS analyzed the data, and
all authors had access to primary clinical trial data.
Patients
Patients aged 418 years with CD34
þ MDS or AML (according
to WHO criteria)
29,30 after allogeneic HSCT, irrespective of
other molecular markers, were eligible for screening at any time
point after HSCT if they had shown a documented CD34
positivity of their leukemic blasts at diagnosis or subsequent
relapse. Key exclusion criteria were as follows: presence of
hematologic relapse; severe hepatic impairment, including
cirrhosis and malignant tumor; renal impairment deﬁned as
serum creatinine more than two times the normal value or
creatinine clearance o50ml/min or participation in a drug
study outside the indication of allogeneic HSCT up to 4 weeks
before study initiation.
Screening
Up to 100 patients were intended to be screened after allogeneic
HSCT to enroll up to 20 patients to the treatment phase. During
screening, CD34
þ donor chimerism in the peripheral blood was
monitored at intervals of 3–4 weeks during the ﬁrst 8 months
after HSCT, and every 7–8 weeks during months 8–24.
However, patients could also enter the screening phase at later
time points after HSCT. On the basis of the data from a previous
study,
23 patients who experienced a drop in CD34
þ donor
chimerism to values below 80% without concurrent hemato-
logic relapse (that is, patients with o5% bone marrow blasts as
obtained at that time point) entered the treatment phase and
were offered treatment with azacitidine.
Treatment
During the 3 weeks before the start of azacitidine treatment,
patients had an initial visit at which they underwent laboratory
tests as well as a bone marrow examination to conﬁrm that they
were still in complete hematologic remission (CR) and therefore
eligible for treatment.
Patients received four cycles of azacitidine (Vidaza; Celgene
Corporation, Summit, NJ, USA) 75mg/m
2/day subcutaneously
on days 1–7, with repeated cycles beginning on day 29±2.
A limited number of azacitidine cycles were administered
because of concerns of sustained myelosuppression as well as
possible induction of GvHD by the study drug at the time of
study design in 2006.
Patients with a major response, deﬁned as an increase of
CD34
þ donor chimerism in the peripheral blood above 80%,
were continuously monitored for a consecutive decrease in
CD34
þ donor chimerism, which, according to protocol,
resulted in re-treatment with four cycles of azacitidine. Patients
with a minor response, deﬁned as an increase of CD34
þ donor
chimerism but to o80%, or a stabilization or further decrease of
CD34
þ donor chimerism in the absence of relapse after four
cycles of treatment, were eligible for an additional four cycles of
azacitidine. Additional treatment was permitted if feasible and
required because of lack of a major response. CD34
þ donor
chimerism was determined 4–6 weeks after completion of the
initial four cycles; therefore, there was a gap in azacitidine
administration of at least 1 month before continuation of
treatment.
Before the start of any subsequent azacitidine cycle, patients
were required to have a leukocyte count 43 10
9/l and platelet
count 450 10
9/l (independent of transfusions). If necessary,
the dose of azacitidine for subsequent cycles was adjusted based
on the leukocyte and platelet nadirs of the preceding cycle, with
67% of the planned azacitidine dose administered for a
leukocyte nadir of 1–3 10
9/l and a platelet nadir of
25–50 10
9/l. In all, 50% of the planned dose was administered
for lower leukocyte or platelet nadirs. Study medication with
azacitidine was discontinued in any patient with hematologic
relapse, renal or hepatic toxicity of grade 3 or higher, or grade
4 hematologic toxicity (deﬁned as leukocyte count o1 10
9/l
or platelet count o25 10
9/l) for 44 weeks after the scheduled
date for continuation of therapy.
In addition, immune suppression could be withdrawn to
support relapse prevention. In the absence of GvHD symptoms,
tacrolimus or cyclosporine could be cautiously reduced to a
maximum of 10% of the total dose per week, starting at any time
from the ﬁrst day of azacitidine treatment. In the case of a new
manifestation of GvHD, any clinically feasible immunosuppres-
sive treatment could be administered.
During azacitidine therapy, antibiotic prophylaxis was
permitted in line with local standards, for example, ciproﬂox-
acin 2 500mg/day orally in case of severe neutropenia
(o0.5 10
9/l neutrophil count).
Cell sorting and CD34
þ donor chimerism analysis from
peripheral blood
Pre-enrichment of CD34
þ cells from peripheral blood using
magnetic beads and subsequent ﬂuorescence-activated cell
sorting was performed as described previously.
23,31 All detect-
able CD34
þ cells were sorted, with a maximum of 10000
CD34
þ cells used for polymerase chain reaction (PCR). In
selected patients, additional CD34
þ cells were used for
conﬁrmatory analysis of cytogenetic markers. The median
number of sorted cells in patients in the screening phase before
treatment was 5000. The median purity, as measured by
repeated ﬂuorescence-activated cell sorting analysis and in
patients with sufﬁcient cell numbers, was 495% (range, 90–
100%). CD34
þ donor chimerism analysis was performed as
recently described in detail.
32 The HumanType Chimera kit
(Biotype, Dresden, Germany) was used to amplify 12 short
tandem repeat loci and the amelogenin gene by PCR from
patients’ CD34
þ cell DNA.
Study end points
The primary end point was the proportion of patients with a
major response after completing four cycles of azacitidine.
Secondary end points were the proportion of patients with a
minor response after completing four cycles of azacitidine, the
proportion of patients with a major or a minor response at
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infectious complications or any of the following toxicities up to
3 months after the last azacitidine cycle: allergy, hepatic or renal
toxicity, acute gastrointestinal toxicity and hematologic toxicity.
Toxicity was graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events version 3.0.
The criteria for premature termination of the clinical trial were
grade 5 infectious complications in over 40% of patients during
azacitidine treatment.
Statistical analysis
Patients were evaluated on an intent-to-treat basis, with all
patients who received at least one dose of study drug included in
the analyzed population. Major and minor response rates after
completing four cycles of azacitidine are reported with exact
Clopper–Pearson conﬁdence intervals. SPSS and SAS were used
as the statistical software. The cutoff date for data inclusion was
1 January 2011.
Results
Patient demographics and disposition
A total of 59 patients entered the screening phase between
January 2007 and February 2010. The majority of patients (90%)
were included immediately after allogeneic HSCT with screening
for CD34
þ donor chimerism starting within 100 days after HSCT
(median 85 days; range, 56–2931 days). A total of 20 patients
experienced a drop of CD34
þ donor chimerism to below 80%
without concurrent signs of hematologic relapse during screen-
ing, and were subsequently enrolled into the treatment phase. All
20 patients received study treatment and comprised the intent-to-
treat population. Their demographics and baseline characteristics
are shown in Table 1 and Supplementary Table S1. The median
age of the treated population was 58 years (range, 20–74 years).
Three patients had International Prognostic Scoring System-
deﬁned High-risk MDS and 17 patients had AML, including 3
patients with secondary AML after MDS. Two patients had
already relapsed after a ﬁrst allogeneic HSCT and had undergone
a second transplantation. All but two patients had received
reduced intensity conditioning before HSCT. Decrease of
CD34
þ donor chimerism to below 80% occurred at a median
of 169 days (range, 61–2919 days) after allogeneic HSCT.
Patients had a median residual CD34
þ donor chimerism of 25%
(range, 0–79%) in peripheral blood. To conﬁrm the speciﬁcity of
the CD34
þ donor chimerism analysis for detection of MRD, we
identiﬁed leukemia-speciﬁc markers (del(5q) and  7) by
ﬂuorescence in situ hybridization in CD34
þ cells of two
representative patients before azacitidine initiation (data not
shown). Additionally, there were two patients in whom the
decrease in CD34
þ donor chimerism was accompanied by a
signiﬁcant increase in MRD as determined by PCR of molecular
markers (nucleophosmin 1
þ mutation and t(8;21); data not
shown). Pre-emptive treatment with azacitidine was started at a
median of 13 days (range, 2–37 days) after the ﬁrst detection of
MRD.
Clinical response after the ﬁrst four azacitidine cycles
Details of the individual patients’ clinical responses after the ﬁrst
four azacitidine cycles are shown in Figure 1 and Supplementary
Table S1, and are summarized as a ﬂow chart in Figure 2. Ten of
20 patients (50%; 95% conﬁdence interval 27–73) achieved an
increase in CD34
þ donor chimerism to over 80% (that is, major
response). Six patients (30%; 95% conﬁdence interval 12–54)
had no increase in CD34
þ donor chimerism to over 80% but
they did not experience hematologic relapse while on azaciti-
dine therapy (that is, minor response). Of these, one patient (5%)
had an increase in CD34
þ donor chimerism, but not to a level
above 80%, whereas the other ﬁve patients (25%) had
stabilization or further decrease of CD34
þ donor chimerism.
Four patients (20%) experienced hematologic relapse during or
after the ﬁrst four azacitidine cycles, with relapse occurring after
the second cycle in two patients, although one of these two
patients showed a temporary increase of CD34
þ donor
chimerism to over 80%. The two other patients relapsed after
the third and fourth azacitidine cycles, respectively. The latter
patient had refractory anemia with excess blasts type 2 with a
Table 1 Patient baseline demographics and disease characteristics
Characteristic n
Total number of patients 20
Sex
Male 11
Female 9
Median age, years (range) 58 (20–74)
Disease
MDS 3
sAML 3
De novo AML 14
Karyotype
Normal 7
 7 and/or inv(3) 5
Complex
a 5
Other 3
Molecular alterations
FLT3-ITD
+ 2
NPM1
+ 1
Disease status prior to HSCT
First CR 5
Second CR 6
b
Third CR 1
First PR 2
Second PR 2
Primary refractory 2
Untreated 2
Donor
Unrelated 14
Related 6
HLA match
HLA-identical 15
One-allele mismatch 3
Haplo-identical 2
Conditioning
Standard 2
Reduced 18
Abbreviations: AML, acute myeloid leukemia; CR, complete remission;
FLT3-ITD
+, FMS-like tyrosine kinase 3 internal tandem duplication;
HLA, human leukocyte antigen; HSCT, hematopoietic stem cell
transplantation; inv, inversion; MDS, myelodysplastic syndromes;
NPM1
+, nucleophosmin 1
+; PR, partial remission; sAML, secondary
AML;  7, monosomy 7.
aDeﬁned as X3 chromosomal abnormalities.
bIncludes two patients who had already relapsed after ﬁrst allogeneic
HSCT.
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Leukemiadel(5q) abnormality, whereas the other three patients had AML
with either normal karyotype (including one with FMS-like
tyrosine kinase 3 internal tandem duplication) or t(8;21). The
three AML patients ultimately died owing to disease progression;
whereas the MDS patient successfully underwent a second
allogeneic HSCT.
Figure 1 Summary of clinical response during azacitidine treatment according to the four patterns observed: major and continued response,
major response and subsequent MRD
þ, minor response and no response. MRD was assessed every 4 weeks. AML, acute myeloid leukemia;
CMML, chronic myelomonocytic leukemia; cmplx, complex (X3 karyotype abnormalities); d, day after ﬁrst detection of CD34
þ donor chimerism
below 80%; del, deletion; FLT3-ITD
þ, FMS-like tyrosine kinase 3 internal tandem duplication; HSCT, hematopoietic stem cell transplantation; inv,
inversion; MRD, minimal residual disease; NK, normal karyotype; NPM1
þ, nucleophosmin 1 mutation; RAEB, refractory anemia with excess
blasts; RCMD, refractory anemia with multilineage dysplasia; sAML, secondary AML; t, translocation; þ6, trisomy 6;  7, monosomy 7.
1The
patient refused further azacitidine treatment and died due to non-azacitidine-related pneumonia, while sustaining CD34
þ donor chimerism
480%.
2The patient died due to progressive disease.
3The patient died due to non-azacitidine-related mesenterial infarction.
4The patient stopped
azacitidine treatment, was taken off protocol, received donor leukocyte infusions and died due to graft-versus-host disease.
Figure 2 Flow chart of the patients’ clinical response and outcome during and after azacitidine treatment. DC, donor chimerism; MRD, minimal
residual disease.
1The patient no. 2 refused further azacitidine treatment and died due to non-azacitidine-related pneumonia, while sustaining
CD34
þ donor chimerism above 80%.
2The patients no. 7 and 8 underwent a second HSCT. Patients no. 5–7, 9 and 10 died due to progressive
disease.
3The patient no. 11 relapsed before additional azacitidine cycles could be initiated.
4The patient no. 11 underwent a second HSCT. Patient
no. 15 died due to progressive disease.
5The patients no. 12 and 14 died due to non-azacitidine-related mesenterial infarction and progressive
disease, respectively.
6The patient no. 20 underwent a second HSCT. Patients no. 17–19 died due to progressive disease.
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LeukemiaClinical response after 6 months: follow-up of
responding patients
Patients with major response (n¼10). Clinical response
at 6 months after the ﬁrst four azacitidine cycles is depicted in
detail in Figure 1 and Supplementary Table S1, and is
summarized in Figure 2. Of the 10 patients with major response
after the ﬁrst four cycles of azacitidine, three patients were still
alive and maintained CD34
þ donor chimerism above 80% with
no relapse at 297, 396 and 998 days after ﬁrst MRD detection,
respectively. An additional AML patient achieved major
response after two initial cycles, but then refused any further
treatment because of personal reasons not related to the study.
This patient died due to pneumonia 8 months after ﬁrst detection
of MRD, still maintaining major response and in CR of the AML.
Six patients experienced a second decrease of CD34
þ donor
chimerism to below 80% at a median of 110 days (range,
48–181 days) after the last cycle of azacitidine. These patients
received a median of four additional cycles (range, 1–8 cycles)
of azacitidine. One of these patients achieved a second major
response after four further cycles of azacitidine (Figure 3). Two
months later, this patient’s CD34
þ donor chimerism dropped
below 80% again and azacitidine was restarted. The patient
achieved a third major response after two additional cycles, but
experienced hematologic relapse B3 weeks after the fourth
cycle. This patient had received a total of 12 cycles of
azacitidine during this study. The other ﬁve patients experienced
a continuous decline in CD34
þ donor chimerism irrespective of
azacitidine re-initiation and subsequently experienced hemato-
logic relapse at 206, 217, 381, 387 and 444 days after ﬁrst MRD
detection, respectively.
Patients with minor response (n¼6). Of the six patients
with minor response after the ﬁrst four cycles of azacitidine, one
patient experienced hematologic relapse before a ﬁfth cycle of
azacitidine could be initiated (170 days after ﬁrst MRD
detection). The other ﬁve patients re-initiated therapy 4–8
weeks after completing the ﬁrst four cycles. Patients received a
median of four additional azacitidine cycles (range, 2–11
cycles), with one patient showing ongoing minor response and
still receiving treatment at the data cutoff date (currently in cycle
9). Two patients relapsed after 3 and 11 additional cycles,
respectively. Of the remaining two patients, one died after two
additional cycles due to mesenteric infarction considered
unrelated to azacitidine, while still in CR. The other patient
stopped treatment with azacitidine after four additional cycles,
while still in CR, but with no increase of CD34
þ donor
chimerism. This patient was taken off the protocol, received DLI
and subsequently died due to GvHD of the gut.
At the time of data cutoff, 13 patients (65%) in the intent-to-
treat population had relapsed within a median of 231 days
(range, 56–558 days) after ﬁrst MRD detection. Four of these
patients successfully underwent a second allogeneic HSCT at a
median of 336 days (range, 199–610 days) after start of
azacitidine. At data cutoff, eight patients (40%), including three
of those who underwent a second allogeneic HSCT, were alive,
with a median follow-up of 487 days (range, 236–1440 days)
after the ﬁrst detection of CD34
þ donor chimerism-deﬁned
MRD.
Safety and tolerability
Reversible grade 3 or 4 neutropenia occurred in 16 of 20
patients (80%) and reversible grade 3 or 4 thrombocytopenia
was observed in 13 of 20 patients (65%) during the ﬁrst four
cycles of azacitidine. Other adverse events included neutrope-
nic fever (n¼4), pneumonia (n¼3) and cytomegalovirus
reactivation (n¼1), which occurred in a total of six patients
Figure 3 Disease course of a patient with repeated major responses following azacitidine treatment. During the ﬁrst four azacitidine cycles the
patient’s immunosuppressive prophylaxis (cyclosporine) was successfully tapered. Approximately 90 days after completing the ﬁrst four cycles of
azacitidine treatment, the patient experienced a second decrease of CD34
þ donor chimerism to o80%. The patient achieved a second major
response with an additional four cycles of azacitidine and treatment was then stopped. Two months later, the patient’s CD34
þ donor chimerism
decreased a third time to below 80% and azacitidine was restarted, resulting in a third major response after two cycles. The patient subsequently
experienced hematologic relapse B3 weeks after cycle four (12 cycles of azacitidine received in total). HSCT, hematopoietic stem cell
transplantation.
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Leukemia(30%). Dose reductions because of myelosuppression were
required in 9 of 20 patients (45%) by the end of the ﬁrst four
cycles of azacitidine, with at least one cycle of treatment
delayed in 6 of 20 patients (30%). During azacitidine treatment,
there was no manifestation of GvHD reported in patients
without a prior history of GvHD. Complete cessation of
immunosuppressive treatment was possible in four of six
patients with no obvious exacerbation of GvHD. Interestingly,
three of these four patients had a history of GvHD before
treatment with azacitidine.
Discussion
Hematologic relapse is a major challenge during the care of
patients with MDS or AML undergoing allogeneic HSCT and
treatment options are currently limited, particularly in patients
with early disease recurrence.
7–9 Previous clinical studies in
patients with MDS and AML after allogeneic HSCT have shown
that low doses of azacitidine (8–40mg/m
2/day for 5 days every
4 weeks) as salvage or maintenance therapy could be a potential
treatment option to prevent or delay hematologic relapse.
27,28 In
both trials, the progression-free and overall survival seemed to
be improved compared with historical approaches without
maintenance, which supports the concept of our study. To our
knowledge, this is the ﬁrst prospective trial investigating a
pharmacological intervention in MDS and AML patients with
MRD and imminent relapse as assessed by sensitive CD34
þ
donor chimerism analysis in peripheral blood. Tracking MRD
after allogeneic HSCT via peripheral blood CD34
þ donor
chimerism monitoring, as performed in this clinical study,
provides the advantage of tailoring azacitidine therapy in a pre-
emptive setting only when MRD is detected, thus avoiding
unnecessary toxicity in patients with ongoing CR. After only four
cycles of azacitidine, MRD was diminished or stabilized in 80%
of patients in the absence of hematologic relapse. Furthermore,
responses were continuous in four of these patients without any
further treatment. This is a remarkable observation, given that
the majority of patients had advanced disease characteristics,
including unfavorable cytogenetic aberrations. It also points to
the unique mode of action of this DNA-methyltransferase
inhibitor.
Nevertheless, for the majority of patients, hematologic relapse
after an initial response could not be ﬁnally prevented, even
with azacitidine re-treatment; 13 patients relapsed at a median
of 231 days after ﬁrst MRD detection (65%). This relapse rate
seems to be comparable to our previous study, which used only
immunotherapeutic interventions to prevent relapse in MDS or
AML patients who had a drop of CD34
þ donor chimerism to
below 80% after HSCT (n¼28).
23 However, when comparing
with the overall historic cohort, the present patient population is
older, and comprises more patients with poor risk karyotype and
advanced disease stages before HSCT. Additionally, in our
previous study relapse was delayed by a median of 61 days from
ﬁrst MRD detection,
23 which is in accordance with other reports
that MRD-guided immunomodulatory measures are often with-
out long-term efﬁcacy in the majority of high-risk diseases.
33
In this trial the time to relapse was considerably prolonged, by
B6 months (median: 231 days), which further supports the
potential of azacitidine to prevent or at least delay relapse in
advanced MDS or AML patients.
Our results also show that a delay of relapse may be of
substantial beneﬁt to patients by allowing for a successful
second HSCT following recovery from early toxicities of the ﬁrst
transplantation. As previous retrospective analyses suggest that
the time interval between ﬁrst transplantation and relapse is of
major relevance for the outcome of second transplantations or
DLI,
5,10 the current strategy could open a window for patients in
whom relapse can be prolonged for another 6–12 months until
DLI or a second allogeneic HSCT can be scheduled.
Because of safety reasons, including possible exacerbation of
GvHD, treatment with azacitidine was limited to four con-
secutive cycles for this ﬁrst phase II study, with the option of
re-treatment if CD34
þ donor chimerism decreased again to
below 80% without hematologic relapse. Severe GvHD was,
however, uncommon and azacitidine treatment was generally
well tolerated in our trial. This represents a substantial
improvement in quality-of-life for these patients when compared
with our historical cohort,
23 where relapse could be delayed
with immunotherapeutic intervention only at the expense of an
extensive chronic GvHD. Furthermore, some patients could
potentially beneﬁt from continued azacitidine treatment, as seen
in other reports.
24,25,34
Hematologic toxicity and infectious complications during
azacitidine treatment were acceptable, with myelosuppression
being both reversible and manageable with dose reduction
or interruption. The use of azacitidine was not associated
with exacerbation of GvHD even in the minority of patients in
whom systemic immunosuppression could be completely
tapered during azacitidine treatment. Recent results in mice
suggest that azacitidine induces FOXP3 expression in naı ¨ve
T-cells, which in turn induces a regulatory T-cell population
that mitigates GvHD while preserving a graft-versus-leukemia
effect.
35,36 Additionally, azacitidine may also augment the
graft-versus-leukemia effect by induction of cytotoxic T-cell
responses or enhance presentation of tumor antigens.
37 These
data provide additional rationale for the combination
of DLI with azacitidine in patients not responding after 4–6
cycles.
In conclusion, this phase II study demonstrated that MRD-
triggered treatment with azacitidine appears to be an effective
strategy for preventing or substantially delaying hematologic
relapse with an acceptable safety proﬁle in patients with MDS or
AML after HSCT. These results support further investigations of
this strategy in larger patient populations using more and
continuous azacitidine cycles, which could potentially further
increase the number of long-term responders.
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